Alyeska Investment Group LP recently announced the acquisition of new stake in Windtree Therapeutics Inc (NASDAQ:WINT). This fresh investment now brings its stake to 2.65% valued currently at $0.15 million. In addition, The Vanguard Group, Inc. raised its holdings by 41640.0 to 41640.0 shares.
With over 0.45 million Windtree Therapeutics Inc (WINT) shares trading Friday and a closing price of $0.72 on the day, the dollar volume was approximately $0.33 million. The shares have shown a negative half year performance of -42.48% and its price on 12/29/23 lost nearly -0.14%. Currently, there are 5.15M common shares owned by the public and among those 4.03M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 16 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, accounting for 1,204,920 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 632 shares.
The top 3 mutual fund holders in Windtree Therapeutics Inc are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F. Vanguard Extended Market Index Fu owns 41640.0 shares of the company’s stock, all valued at over $47053.0. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.01% of the shares outstanding.
However, the script later moved the day high at 0.7400, down -0.14%. The company’s stock has a 5-day price change of -0.64% and -24.20% over the past three months. WINT shares are trading -91.54% year to date (YTD), with the 12-month market performance down to -90.97% lower. It has a 12-month low price of $0.70 and touched a high of $19.06 over the same period. WINT has an average intraday trading volume of 123.63K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.48%, -23.32%, and -57.97% respectively.
Institutional ownership of Windtree Therapeutics Inc (NASDAQ: WINT) shares accounts for 4.04% of the company’s 5.15M shares outstanding. Mutual fund holders own 2.13%, while other institutional holders and individual stakeholders account for 2.96% and 1.08% respectively.
It has a market capitalization of $3.70M and a beta (3y monthly) value of 0.59. The earnings-per-share (ttm) stands at -$19.81. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.43% over the week and 9.29% over the month.
Analysts forecast that Windtree Therapeutics Inc (WINT) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$6.5 a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Windtree Therapeutics Inc (WINT) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the WINT, a number of firms have released research notes about the stock. Ladenburg Thalmann stated their Buy rating for the stock in a research note on June 26, 2020, with the firm’s price target at $12.25.
